


BEST OF EASL

UPDATES AND HIGHLIGHT FROM THE LIVER CONGRESS 2026 IN BARCELONA

 SATURDAY, 29 AUGUST 2026

CLICK HERE FOR REGISTRATION



MODERATOR: DR. ADEL ALQUTUB

 TIME	 TOPIC	 SPEAKER
13:00 - 13:20	Viral Hepatitis	Dr. Karim Qumosani
13:20 - 13:40	MASLD	Dr. Saad Aldosary
13:40 - 14:00	HCC and Liver Transplantation	Dr. May Alzahrani
14:00 - 14:20	Satellite Symposium by GSK The evolving landscape of HBV: translating the latest evidence into a path for functional cure	Dr. Faisal Abaaalkhail
14:20 - 14:40	Autoimmune & Cholestatic Liver Diseases	Dr. Noora H Alfaraj
14:40 - 15:00	Pediatric Hepatology	Dr. Mohammed Shagrani
15:00 - 15:15	Saudi Contributions at EASL 2026	Dr. Basma Khoja
15:15 - 15:30	Q&A	



MODERATED BY
DR. ADEL ALQUTUB



SPEAKER
Dr. FAISAL ABAALKHAIL



SPEAKER
Dr. KARIM QUMOSANI



SPEAKER
Dr. SAAD ALDOSARY



SPEAKER
Dr. MAY ALZAHANI



SPEAKER
Dr. NOORA H ALFARAJ



SPEAKER
Dr. MOHAMMED SHAGRANI



SPEAKER
Dr. BASMA KHOJA




SATURDAY
29 AUGUST 2026



13:00 - 15:30
KSA TIME



WEBINAR
VIRTUAL



**GOLD
SPONSOR**

GSK

**SILVER
SPONSORS**



Research and development approach



By combining the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines to help transform people's lives.



R&D is at the heart of our innovation

Innovation to help people live not just longer but healthier lives is needed more now than ever before. Populations are ageing, disease burdens are becoming more complex, and health systems are under increasing pressure.

Our R&D approach combines the science of the immune system with advanced technologies, enhanced by targeted business development and world-class partnerships. This approach enables us to develop new medicines and vaccines that can make a difference to patients' lives, and create value for health systems, shareholders and society.

Patients are at the heart of everything we do – we engage with them and their healthcare providers to deeply understand the impact of disease and deliver innovation where it matters most.

Our R&D priorities

Three priorities guide our R&D. These priorities are helping us create more focus and opportunity in our pipeline than ever before. Since 2016, our R&D investment has increased by over 90%. We have 58 assets in our pipeline with over half of these coming through business development.



Execution



Technology



Culture